Make notes on- drug resistance in gonorrhoea and surveillance strategies, t/t guidelines, for md derma theory exam from recent updates
Reading File
Reading File
Finding Sources
Finding Sources
Searching the Web
CDC 2024 2025 gonorrhea treatment guidelines antimicrobial resistance surveillance update
Searching PubMed
"Neisseria gonorrhoeae" AND "antimicrobial resistance" AND surveillance
Reading File
Reading File
Reading Article
PMID: 40862332
Reading Article
PMID: 40205910
Reading Web Page
https://www.cdc.gov/std/treatment-guidelines/gonorrhea.htm
Searching the Web
WHO Gonococcal Antimicrobial Surveillance Programme GASP EGASP 2024 2025 ceftriaxone resistance
Searching the Web
NACO IADVL national guidelines STI gonorrhea treatment India 2024 ceftriaxone
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC12716636
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC12547025
Finding Sources
Searching PubMed
zoliflodacin gepotidacin gonorrhea
Reading File
Finding Sources
Drug Resistance in Gonorrhoea: Surveillance Strategies and Treatment Guidelines
MD Derma Theory Notes (Updated 2024-2025)
1. Why This Topic Matters
N. gonorrhoeae has sequentially developed resistance to every antibiotic class deployed against it over 80+ years, and ceftriaxone (the current last-line empirical drug) is now failing in several countries. WHO has flagged it as a priority AMR pathogen (Fifer & Johnson, J Antimicrob Chemother 2025, PMID 40205910).
2. Evolution of Resistance (Mechanism-wise) - Historical Framework
| Era/Drug | Resistance mechanism | Result |
|---|---|---|
| Sulfonamides (1930s-40s) | Chromosomal mutation | Rapid, near-universal resistance |
| Penicillin | PPNG - plasmid-borne β-lactamase (penicillinase-producing N. gonorrhoeae), spread worldwide by early 1980s | Penicillin abandoned |
| Tetracycline | Plasmid-borne (TRNG) + chromosomal mutations | Tetracycline abandoned |
| Fluoroquinolones | gyrA/parC mutations (QRNG - quinolone-resistant N. gonorrhoeae) | CDC withdrew ciprofloxacin from guidelines (2007); no longer recommended anywhere except when a molecular gyrase-A assay confirms susceptibility |
| Azithromycin | 23S rRNA mutations, mtr efflux pump upregulation | Rising resistance (>5% threshold triggers WHO guideline review) - dual therapy largely abandoned in the US since 2020/2021 CDC update |
| Cephalosporins (cefixime, ceftriaxone) | Mosaic penA alleles (e.g., penA-60.001, penA-237.001), altered PBP2 | Basis of current global concern - ceftriaxone treatment failures reported (UK, Australia, Japan, Austria, France, Cambodia, Thailand, Vietnam) |
(Harrison's 22E; Jawetz Melnick & Adelberg's Medical Microbiology 28E; Goldman-Cecil Medicine)
Key exam point: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) gonococcal strains are now clonally expanding in some regions - XDR isolates resistant to ceftriaxone AND azithromycin have been documented.
3. Current Global Resistance Burden (Recent Data)
- WHO's Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) 2025 report (data from 2024, 13 countries, 5 WHO regions): rising resistance to ceftriaxone and azithromycin globally.
- Vietnam (EGASP sentinel data, 2024) - a striking recent example for exam use:
- Ceftriaxone resistance: 32.4% (up from 26.9% in 2023)
- Cefixime resistance: 37.3%
- Azithromycin resistance: 7.9%
- XDR strains clonally expanding (driven by mosaic penA-237.001 and penA-60.001 alleles)
- 69.8% of ceftriaxone-resistant isolates carried non-penA-60.001 alleles - meaning standard PCR assays targeting penA-60.001 can miss them, underscoring the need for whole-genome sequencing (WGS) in surveillance. (Pham Thi Lan et al., Lancet Reg Health West Pac 2025, PMID 41140782)
- Canada (2017-2024 national surveillance): 13 confirmed ceftriaxone-resistant isolates; azithromycin resistance has crossed the WHO 5% action threshold in the most populous provinces.
4. Surveillance Strategies (Exam-Focused)
A. Global level
- WHO GASP (Gonococcal Antimicrobial Surveillance Programme) - the original global network (since 1990s) tracking susceptibility trends via regional/national reference labs; feeds into GLASS (Global Antimicrobial Resistance and Use Surveillance System) and WHO's Global Action Plan on AMR.
- WHO EGASP (Enhanced GASP) - the newer, more rigorous sentinel-site model:
- Standardized protocols, quality-assured MIC testing (agar dilution/Etest), demographic + clinical linkage
- Expanded from 4 countries (2015-2022 data) → 9 (2023 report) → 13 countries across 5 regions (2024 report)
- Incorporates test-of-cure, extragenital site sampling, and whole-genome sequencing (WGS) frameworks
- Includes a treatment-failure surveillance protocol
B. National/regional programmes (mention for comparison)
- GISP (Gonococcal Isolate Surveillance Project) - USA/CDC
- Euro-GASP - ECDC, Europe
- NACO STI/RTI surveillance - India (through designated STI reference labs, feeds into NACO 2024 guideline updates)
C. Core surveillance tools/strategies to name in exam
- Culture-based antimicrobial susceptibility testing (AST) - agar dilution/E-test MIC determination (gold standard, but culture facilities limited in low-resource settings)
- Molecular resistance-prediction assays (e.g., real-time PCR for penA, gyrA mutations) - faster but can miss novel alleles (as shown in Vietnam data above)
- Whole-genome sequencing (WGS) - now considered essential to detect emerging/novel resistance alleles missed by targeted PCR
- Point-of-care resistance testing - emerging technology (Melendez & Manabe review, Clin Infect Dis 2026, PMID 41504562)
- Test-of-cure (NAAT-based) after treatment - both a clinical and surveillance tool
- Sentinel surveillance in high-risk groups (MSM, sex workers, extragenital sites - pharyngeal/rectal, where resistance often emerges first)
5. Current Treatment Guidelines - Comparative Table
| Indication | CDC 2021 STI Guidelines (US) | NACO 2024 (India) |
|---|---|---|
| Uncomplicated urogenital/rectal gonorrhoea | Ceftriaxone 500 mg IM single dose (<150 kg; 1 g if ≥150 kg). Add doxycycline 100 mg BD × 7 days if chlamydia not excluded. No test-of-cure needed | Ceftriaxone 500 mg IM stat (>150 kg → 1 g); alternatives - Cefixime 800 mg stat, or Gentamicin 240 mg IM + Azithromycin 2 g (not in pregnancy) |
| Pharyngeal gonorrhoea | Ceftriaxone 500 mg IM (test-of-cure recommended 7-14 days later - pharynx is the site most prone to treatment failure) | Ceftriaxone 500 mg IM stat |
| Gonococcal conjunctivitis (adult) | Ceftriaxone 1 g IM single dose | Ceftriaxone 1 g IM + saline lavage of eye |
| Ophthalmia neonatorum | Ceftriaxone 25-50 mg/kg IV (max 125 mg) single dose | - |
| Disseminated GC infection | Ceftriaxone 1 g IM/IV q24h (initial) → step-down to cefixime 400 mg PO BID | - |
| PID/NGU with GC+CT co-infection | Ceftriaxone 500 mg IM + Doxycycline 100 mg BD × 10-14 days (± metronidazole for PID) | Similar combination regimens; levofloxacin added in select MSM/heterosexual scenarios |
| Pregnancy | Ceftriaxone 500 mg IM + doxycycline alternative cover (avoid gentamicin - ototoxic/nephrotoxic risk) | Similar - avoid gentamicin |
| Cephalosporin-allergic/resistant strains | Gentamicin 240 mg IM + Azithromycin 2 g PO single dose | Gentamicin 240 mg IM + Azithromycin 2 g |
| Suspected treatment failure | Retreat with ceftriaxone 500 mg IM regimen first (reinfection more likely than true failure); if failure suspected, culture + AST before retreatment | Test-of-cure + gentamicin/azithromycin combination; partner treatment for contacts in preceding 60 days |
Key change to emphasize in exam: Dual therapy (ceftriaxone + azithromycin) for uncomplicated gonorrhoea was discontinued in the CDC 2020/2021 update — ceftriaxone monotherapy (at a higher dose than the old 250 mg) is now preferred in the US, specifically to reduce selection pressure driving azithromycin resistance and preserve azithromycin for chlamydia/other uses. European (BASHH/IUSTI) guidelines still recommend ceftriaxone 1 g + azithromycin 2 g as dual therapy — an important US-vs-Europe-vs-India contrast point for viva.
Follow-up principles (universal):
- Partner treatment for all sexual contacts within preceding 60 days
- Abstinence until 7 days post-treatment completion and symptom resolution
- Re-screening at 3 months (high reinfection rates)
- Test-of-cure mandatory for: pharyngeal infection, pregnancy, non-first-line regimens, or known/suspected resistant strain
(Sources: Harrison's Principles of Internal Medicine 22E, Table 161-1; Goldman-Cecil Medicine; NACO 2024 vs CDC 2021 comparison — Ready Reckoner for PG Dermato-venereologists, PMC12716636)
6. New Antibiotics in the Pipeline (High-yield "recent updates" point)
| Drug | Class/mechanism | Status (2025-26 data) |
|---|---|---|
| Zoliflodacin | Novel spiropyrimidinetrione, inhibits DNA gyrase/topoisomerase IV (new target, no cross-resistance with fluoroquinolones) | Phase 3 non-inferiority trial vs ceftriaxone+azithromycin showed benefit for oral treatment of uncomplicated gonorrhoea (Lancet 2025-26, PMID 41391464); moving toward licensure |
| Gepotidacin | Triazaacenaphthylene, novel bacterial topoisomerase inhibitor | Non-inferior to ceftriaxone + azithromycin for urogenital gonorrhoea in trials (Lancet 2025, PMID 40245903) |
| Cross-resistance concern | Emerging in vitro data show possible zoliflodacin-gepotidacin cross-resistance via shared target mutations (2025 preprint) - relevant caution for future stewardship |
Both agents are oral, single-target novel mechanisms - major potential answer to the ceftriaxone-resistance crisis, but require careful stewardship once approved to avoid repeating the cephalosporin/azithromycin resistance story.
7. High-Resource vs Limited-Resource Settings (Global Health angle - good for discussion-type questions)
Per Tanasov et al. (Int J Dermatol 2026, PMID 40862332):
- High-resource settings: molecular NAAT diagnostics, culture-based AST, structured surveillance (GISP/Euro-GASP/EGASP), test-of-cure protocols — yet resistance still rising.
- Limited/no-resource settings: reliance on syndromic management (low sensitivity, misses asymptomatic infection), poor lab capacity for AST, driving empirical/inappropriate antibiotic use — a major driver of resistance emergence and spread to migrant/vulnerable populations.
- WHO's equity-focused strategy: expand molecular testing access, build local surveillance capacity, tailor stewardship interventions regionally.
8. Exam-Ready Summary Points to Remember
- Ceftriaxone = current last reliable first-line drug; monotherapy (US) vs dual therapy with azithromycin (Europe).
- Resistance mechanism keywords: PPNG, TRNG, QRNG, mosaic penA alleles (cephalosporin resistance), 23S rRNA mutations (azithromycin resistance).
- Surveillance: WHO GASP → EGASP (current gold-standard global programme) + GLASS integration + WGS for allele detection.
- India: NACO 2024 guidelines — largely mirror CDC but retain gentamicin+azithromycin as an explicit alternative and require test-of-cure in more scenarios than CDC.
- Pipeline drugs: zoliflodacin and gepotidacin — novel mechanism oral agents, both in advanced trials/near licensure as of 2025-26.
- Vietnam EGASP 2024 data (32.4% ceftriaxone resistance) is currently the most cited real-world example of the crisis — good case-study to quote.
Recent-evidence check (per protocol): A search for meta-analyses/systematic reviews on this topic in the last 2 years returned mainly narrative reviews (evidence tier 7) rather than tier 1/2 studies — e.g., Fifer & Johnson 2025 (PMID 40205910) and the tetracycline-resistance systematic review by Do/Unemo/Kenyon 2025 (PMID 40636396, relevant to doxycycline PEP policy). No tier 1-2 evidence was found to contradict the guideline positions summarized above; these reviews support and update them.
This is a shared conversation. Sign in to Orris to start your own chat.